{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:57:20Z","timestamp":1793246240617,"version":"4.5.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The survival rates of patients with hematological malignancies such as multiple myeloma have improved with advances in cancer treatment. However, the risk of cardiovascular disease associated with novel therapeutic agents, including proteasome inhibitors (PIs), is becoming increasingly evident. PIs act on proteasome peptidases, leading to cell cycle arrest or apoptosis. Carfilzomib (CFZ), an intravenously administered irreversible PI, exhibits pronounced cardiovascular toxicity that is characterized by heart failure, hypertension, arrhythmia, and ischemic heart disease (IHD). This review focuses on CFZ, details its applications in treating multiple myeloma, presents its potential mechanisms of cardiotoxicity and the incidence of cardiotoxic events, and provides recommendations for the evaluation and management of adverse cardiac events during the early treatment of patients with this drug.<\/jats:p>","DOI":"10.3389\/fphar.2025.1570017","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:09:14Z","timestamp":1743113354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lintao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15617","DOI":"10.3390\/ijms232415617","article-title":"Zingerone attenuates carfilzomib-induced cardiotoxicity in rats through oxidative stress and inflammatory cytokine network","volume":"23","author":"Alam","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers15030955","article-title":"Carfilzomib-based regimen and cardiotoxicity in multiple myeloma: incidence of cardiovascular events and organ damage in carfilzomib-dexamethasone versus carfilzomib-lenalidomide-dexamethasone. A real-life prospective study","volume":"15","author":"Astarita","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/01.hyp.24.3.322","article-title":"Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats","volume":"24","author":"Bank","year":"1994","journal-title":"Hypertension"},{"key":"B4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","article-title":"Case report: carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with eculizumab","volume":"20","author":"Bhutani","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12882","article-title":"Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension","volume":"286","author":"Bringhen","year":"2019","journal-title":"J. Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bcmd.2009.01.021","article-title":"Chemical crosslinking studies with the mouse Kcc1 K-Cl cotransporter","volume":"42","author":"Casula","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clinbiochem.2014.10.013","article-title":"Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity","volume":"48","author":"Christenson","year":"2015","journal-title":"Clin. Biochem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s0195-668x(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur. Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/jco.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/s2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"114907","DOI":"10.1016\/j.biopha.2023.114907","article-title":"Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway","volume":"164","author":"Dabour","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00204-024-03913-0","article-title":"Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells","volume":"99","author":"Dabour","year":"2025","journal-title":"Arch. Toxicol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/eurheartj\/ehad115","article-title":"Proteomic cardiovascular risk assessment in chronic kidney disease","volume":"44","author":"Deo","year":"2023","journal-title":"Eur. Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"B20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1129943","DOI":"10.3389\/fcvm.2023.1129943","article-title":"Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse population","volume":"10","author":"Doran","year":"2023","journal-title":"Front. Cardiovasc Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.3390\/ijms21155185","article-title":"Investigating the vascular toxicity outcomes of the irreversible proteasome inhibitor carfilzomib","volume":"21","author":"Efentakis","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"10956","DOI":"10.3390\/ijms222010956","article-title":"Elucidating carfilzomib's induced cardiotoxicity in an in vivo model of aging: prophylactic potential of metformin","volume":"22","author":"Efentakis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1111\/bph.16391","article-title":"Implications and hidden toxicity of cardiometabolic syndrome and early-stage heart failure in carfilzomib-induced cardiotoxicity","volume":"181","author":"Efentakis","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jama.2024.3737","article-title":"Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications","volume":"331","author":"Feero","year":"2024","journal-title":"Jama"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","article-title":"Optimising cardiovascular care of patients with multiple myeloma","volume":"107","author":"Fontes Oliveira","year":"2021","journal-title":"Heart"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e022247","DOI":"10.1161\/jaha.121.022247","article-title":"Carfilzomib treatment causes molecular and functional alterations of human induced pluripotent stem cell-derived cardiomyocytes","volume":"10","author":"Forghani","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-020-00381-4","article-title":"Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients","volume":"10","author":"Fotiou","year":"2020","journal-title":"Blood Cancer J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e029689","DOI":"10.1161\/jaha.123.029689","article-title":"Causal association between anemia and cardiovascular disease: a 2-sample bidirectional mendelian randomization study","volume":"12","author":"Gan","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/s1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/antiox13060671","article-title":"Empagliflozin alleviates carfilzomib-induced cardiotoxicity in mice by modulating oxidative stress, inflammatory response, endoplasmic reticulum stress, and autophagy","volume":"13","author":"George","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"Jama"},{"key":"B39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ejh.13709","article-title":"Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group","volume":"108","author":"Gregersen","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41419-020-03005-8","article-title":"Crosstalk between cardiomyocytes and noncardiomyocytes is essential to prevent cardiomyocyte apoptosis induced by proteasome inhibition","volume":"11","author":"Guo","year":"2020","journal-title":"Cell Death Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc Toxicol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/cvr\/cvp226","article-title":"Proteasome inhibitors and cardiac cell growth","volume":"85","author":"Hedhli","year":"2010","journal-title":"Cardiovasc Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.jtha.2024.03.024","article-title":"The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium","volume":"22","author":"Hjazi","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B45","doi-asserted-by":"publisher","first-page":"101926","DOI":"10.1016\/j.jsps.2023.101926","article-title":"Oxyphenbutazone ameliorates carfilzomib induced cardiotoxicity in rats via inhibition of oxidative free radical burst and NF-\u03baB\/I\u03baB-\u03b1 pathway","volume":"32","author":"Imam","year":"2024","journal-title":"Saudi Pharm. J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12012-015-9356-5","article-title":"Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-\u03baB, hypertrophic gene expression and oxidative stress","volume":"17","author":"Imam","year":"2017","journal-title":"Cardiovasc Toxicol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.sbi.2014.02.002","article-title":"Paradigms of protein degradation by the proteasome","volume":"24","author":"Inobe","year":"2014","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1003454","DOI":"10.1371\/journal.pmed.1003454","article-title":"Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): interim analysis of an open-label randomised controlled trial","volume":"18","author":"Jackson","year":"2021","journal-title":"PLoS Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12012-023-09785-7","article-title":"Molecular cardiotoxic effects of proteasome inhibitors carfilzomib and ixazomib and their combination with dexamethasone involve mitochondrial dysregulation","volume":"23","author":"Jannuzzi","year":"2023","journal-title":"Cardiovasc Toxicol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1182\/blood.V120.21.2916.2916","article-title":"Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice","volume":"120","author":"Kistler","year":"2012","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur. J. Intern Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/s1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1871529x21666210412113017","article-title":"Incidence and management of carfilzomib-induced cardiovascular toxicity; A systematic review and meta-analysis","volume":"21","author":"Latif","year":"2021","journal-title":"Cardiovasc Hematol. Disord. Drug Targets"},{"key":"B56","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1161\/hypertensionaha.117.10390","article-title":"Novel role for the immunoproteasome subunit PSMB10 in angiotensin II-induced atrial fibrillation in mice","volume":"71","author":"Li","year":"2018","journal-title":"Hypertension"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"176112","DOI":"10.1016\/j.ejphar.2023.176112","article-title":"Kaempferol protects against cardiovascular abnormalities induced by nitric oxide deficiency in rats by suppressing the TNF-\u03b1 pathway","volume":"960","author":"Maneesai","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/14779072.2017.1409114","article-title":"Cardiovascular complications of multiple myeloma in the elderly","volume":"15","author":"Mathur","year":"2017","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S2152-2650(21)02285-0","article-title":"P-158: carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion","volume":"21","author":"Mendez","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph8010001","article-title":"Clinical use of proteasome inhibitors in the treatment of multiple myeloma","volume":"8","author":"Merin","year":"2014","journal-title":"Pharm. (Basel)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41408-021-00492-6","article-title":"Real-world renal function among patients with multiple myeloma in the United States","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/biomedicines10030602","article-title":"Reactive oxygen species induced pathways in heart failure pathogenesis and potential therapeutic strategies","volume":"10","author":"Mongirdien\u0117","year":"2022","journal-title":"Biomedicines"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/s0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000519687","article-title":"Evaluation of cardiac adverse events associated with carfilzomib using a Japanese real-world database","volume":"100","author":"Nakao","year":"2022","journal-title":"Oncology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.18632\/oncotarget.24882","article-title":"Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-cell type- and drug-dependent","volume":"9","author":"Papanagnou","year":"2018","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/hco.0000000000000619","article-title":"Risk factors for chemotherapy-related cardiac toxicity","volume":"34","author":"Polonsky","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","article-title":"Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis","volume":"59","author":"Shah","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B73","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/jco.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2024.02.029","article-title":"Changes in global longitudinal strain as a predictor of cardiotoxicity after exposure to carfilzomib","volume":"217","author":"Singh","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cvr\/cvp315","article-title":"The ubiquitin-proteasome pathway and endothelial (dys)function","volume":"85","author":"Stangl","year":"2010","journal-title":"Cardiovasc Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1096\/fj.03-0054com","article-title":"Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway","volume":"18","author":"Stangl","year":"2004","journal-title":"Faseb J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1816287","DOI":"10.1155\/2019\/1816287","article-title":"The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma","volume":"2019","author":"Takakuwa","year":"2019","journal-title":"Case Rep. Hematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12185-020-03013-6","article-title":"Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR","volume":"113","author":"Takezako","year":"2021","journal-title":"Int. J. Hematol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-023-00882-y","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma","volume":"13","author":"Tan","year":"2023","journal-title":"Blood Cancer J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"104961","DOI":"10.1016\/j.ebiom.2023.104961","article-title":"CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy","volume":"100","author":"Tang","year":"2024","journal-title":"EBioMedicine"},{"key":"B82","doi-asserted-by":"publisher","first-page":"645122","DOI":"10.3389\/fcvm.2021.645122","article-title":"Lactate dehydrogenase B and pyruvate oxidation pathway associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: result of a multi-omics integrative analysis","volume":"8","author":"Tantawy","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00277-008-0554-0","article-title":"Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor","volume":"88","author":"Vela-Ojeda","year":"2009","journal-title":"Ann. Hematol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"994384","DOI":"10.3389\/fcvm.2022.994384","article-title":"Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/biology13100844","article-title":"Short-term proteasome inhibition: assessment of the effects of carfilzomib and bortezomib on cardiac function, arterial stiffness, and vascular reactivity","volume":"13","author":"Wesley","year":"2024","journal-title":"Biol. (Basel)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1001\/jama.2024.5217","article-title":"Heart failure in african American individuals, version 2.0","volume":"331","author":"Yancy","year":"2024","journal-title":"Jama"},{"key":"B89","doi-asserted-by":"publisher","first-page":"20406207211019612","DOI":"10.1177\/20406207211019612","article-title":"The role of carfilzomib in relapsed\/refractory multiple myeloma","volume":"12","author":"Yee","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3324\/haematol.2021.278399","article-title":"Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)","volume":"106","author":"Yong","year":"2021","journal-title":"Haematologica"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1570017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:09:20Z","timestamp":1743113360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1570017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":90,"alternative-id":["10.3389\/fphar.2025.1570017"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1570017","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1570017"}}